First established by French immunologist Daniel Zagury, M.D, PhD., as a spinoff of Pierre et Marie Curie University. Neovacs became a biotechnology company in 2003 when several investment funds specialized in healthcare industry joined the capital.

Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune, inflammatory diseases, allergies and cancers.


Our ambition

“Our goal is to become a leading player in the treatment of chronic autoimmune and inflammatory  diseases and certain types of cancers, through the use of  the Kinoid® technology. Our goal is to advance research  and provide patients with well tolerated and more efficient treatments, while reducing healthcare expenditures.” said Miguel Sieler, CEO of Neovacs.

Our Pipeline

IFNα Kinoid: this “anti-interferon-alpha” vaccine, is now the most advanced product of Neovacs research. It is currently in clinical development in lupus and dermatomyositis.

pipeline V6 (2)



Where to find us


3-5, Impasse Reille

75014 PARIS



Tel. : 33 (0)1 53 10 93 00

Fax : 33 (0)1 53 10 93 03

Why should you invest in Neovacs?

go to the investors section